About

Targeted Therapeutics for Cancer and Ophthalmology

Company Overview

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. We retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.

We operate a clinical development model that emphasizes capital efficiency. Our experienced clinical operations and regulatory affairs groups enable us to eliminate the cost associated with hiring contract research organizations to manage clinical, regulatory and database aspects of our Phase 1 and Phase 2 clinical trials. We have also collaborated with the National Cancer Institute, which has selected TRC105 and TRC102 for federal funding of clinical development, as well as Case Western Reserve University. Under these collaborations, NCI has sponsored or is sponsoring seven completed or ongoing clinical trials of TRC105 and TRC102, and Case Western is sponsoring two ongoing clinical trials of TRC102.

Our goal is to be a leader in the development of targeted therapies for patients with cancer and other diseases of high unmet need. Key components of our strategy are:

  • Focus clinical development of TRC105 on initial oncology indications with potential reduced time to regulatory approval;
  • Expand development program for TRC105 into large market oncology indications;
  • Continue to leverage our collaborative relationship with NCI to accelerate and broaden development of TRC105 and TRC102;
  • Support Santen during preclinical development to advance its product candidate licensed from us into clinical trials in wet AMD;
  • Continue preclinical studies and initiate clinical development of TRC205 in fibrotic diseases; and
  • Leverage internal capabilities to advance other programs efficiently and cost effectively through clinical development.
Copyright © TRACON Pharmaceuticals, Inc. 2015